Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
AB001
i
Other names:
AB001, 212Pb-NG001, AB 001, AB-001
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
ARTBIO, AlphaGen Therapeutics
Drug class:
Alpha radiation emitter, PSMA inhibitor
Related drugs:
‹
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
radium Ra-223 dichloride (2)
ORM-2110 (1)
BAY2701439 (1)
I-131-apamistamab (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
AAA817 (0)
CONV01-α (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
Iomab-ACT (0)
JNJ-6420 (0)
VMT-01 (0)
VMT-𝛼-NET (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
BAY 2287411 (0)
lutetium Lu 177 vipivotide tetraxetan (4)
PNT2002 (2)
225Ac-FL-020 (1)
INO-5401 (1)
JNJ-63898081 (1)
177Lu-LNC1003 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
AB-2100 (0)
ALF501 (0)
CB307 (0)
CBP-1018 (0)
CC-1 (0)
CCW702 (0)
HPN424 (0)
INO-5150 (0)
BIND-014 (0)
177 Lu-FC705 (0)
AMG 160 (0)
G-202 (0)
REGN5678 (0)
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
radium Ra-223 dichloride (2)
ORM-2110 (1)
BAY2701439 (1)
I-131-apamistamab (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
AAA817 (0)
CONV01-α (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
Iomab-ACT (0)
JNJ-6420 (0)
VMT-01 (0)
VMT-𝛼-NET (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
BAY 2287411 (0)
lutetium Lu 177 vipivotide tetraxetan (4)
PNT2002 (2)
225Ac-FL-020 (1)
INO-5401 (1)
JNJ-63898081 (1)
177Lu-LNC1003 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
AB-2100 (0)
ALF501 (0)
CB307 (0)
CBP-1018 (0)
CC-1 (0)
CCW702 (0)
HPN424 (0)
INO-5150 (0)
BIND-014 (0)
177 Lu-FC705 (0)
AMG 160 (0)
G-202 (0)
REGN5678 (0)
›
Associations
News
Trials
Filter by
Latest
1year
Phase 0/1 Study of 212Pb-NG001 in mCRPC (clinicaltrials.gov)
P1, N=3, Completed, ARTBIO Inc. | Recruiting --> Completed | N=23 --> 3
1 year ago
Trial completion • Enrollment change • Metastases
|
AB001
over1year
Phase 0/1 Study of 212Pb-NG001 in mCRPC (clinicaltrials.gov)
P1, N=23, Recruiting, ARTBIO Inc. | Not yet recruiting --> Recruiting
over 1 year ago
Enrollment open • Metastases
|
AB001
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login